Screener / SEC EDGAR /CIK 0001991792 /10-K filed Feb 27, 2026, compared with Mar 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

CG Oncology, Inc. CGON

Compare with peers Embed
CEO pay, fiscal year to Dec 31, 2025

Arthur Kuan was paid $11.9M as reported, $28.6M at the share price

Proxy (DEF 14A)
CEO pay, as reported $11.9M salary, bonus and awards at grant value
CEO pay, actually paid $28.6M awards valued at the share price
$100 in the shares became $112 peer group: $131
CEO pay, 2 years $23.1M up 7% while the company lost money

Pay against results, year by year

Pay versus performance · proxy, filed Apr 24, 2026

Fiscal year toCEOCEO pay (reported) CEO pay (actually paid) $100 became
Dec 31, 2025Arthur Kuan $11.9M$28.6M $112
Dec 31, 2024Arthur Kuan $11.2M$23.4M $77

Pay versus performance table of the proxy statement (DEF 14A) filed Apr 24, 2026, as tagged by the company in XBRL. Open the proxy

Pay against free cash flow per share, at peers

Change over the years each proxy covers · pay versus performance table, DEF 14A, and 10-K XBRL

CEO pay, as reported Free cash flow per share » runs past the edge. Pay is salary, bonus and awards at grant value. FCF per share is cash from operations less capital spending, over diluted shares, from the 10-K of the same fiscal year.

CGON: CEO pay rose 7% from FY2024 to FY2025 ($11.2M to $11.9M). Open the proxy

Sources

The pay versus performance table of the latest proxy statement, as the company tagged it in XBRL.

Also

Cash & buybacks: what the company did with its cash in the same years.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CGON/export.csv") into a cell.

Next:Crypto holdings
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.